Proteome advances CK1D inhibitors in Tau approach to Alzheimer's
This article was originally published in Scrip
Executive Summary
The proteomics and peptidomics company Proteome Sciences is looking for pharma company partners to take its novel CK1D inhibitors into the clinic in Alzheimer's disease after achieving in vivo proof of concept for the oral compounds.